字号·· | 护眼
路透社

CVS表示:GLP-1类药物月价格低于350美元即可省钱CVS says GLP-1s save money when priced below $350 per month

点「原文对照」整页切到原文,或双击某段只看那段的原文。

约克 11月14日电 —— CVS健康公司表示,如果GLP-1类药物的定价低于每人每月350美元,雇主和其他医疗计划赞助方就能在这类药物上实现收支平衡,因为住院和急诊就医等医疗服务使用的减少,能够节省足够的开支来抵消药费。

YORK, Nov 14 - CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug costs.

CVS表示,对旗下安泰保险理赔数据的分析发现,在肥胖、糖尿病或其他疾病患者群体中,GLP-1类药物目前的售价因为过高而无法被较低的医疗成本所对冲,从而增加了支出。

CVS said that an analysis of its Aetna insurance claims data found that across patients with obesity, diabetes or other conditions, the current prices for GLP-1 drugs add to spending because they are too high to be impacted by lower medical costs.

该分析观察了开始服用礼来公司和诺和诺德公司出品的极受欢迎的GLP-1新药的患者 —— 这类药物能模仿GLP-1激素并降低食欲 —— 并将其与未服用这些药物的类似患者进行了对比。

The analysis looked at patients who were newly taking highly popular GLP-1 medicines — which mimic the GLP-1 hormone and reduce appetite — from Eli Lilly and Novo Nordisk, and compared them to similar patients who were not taking the drugs.

这些药物包括用于治疗糖尿病的Mounjaro和Ozempic,以及用于治疗肥胖的Zepbound和Wegovy。该分析涵盖了最长达三年的时间段,患者开始服药的时间在2023年至2025年之间。该分析没有单独列出肥胖患者的数据。

The drugs included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity. The analysis covered periods of up to three years, with patients starting the medicines between 2023 and 2025. The analysis did not break out figures for obesity patients alone.

GLP-1覆盖范围因成本而缩小 随着企业和其他医疗计划赞助方试图降低预计将在2027年上涨逾9%的保费,针对肥胖症的GLP-1药物医保覆盖范围正在缩小。约有14%的公司已经取消或计划在2027年取消这些药物的覆盖。

GLP-1 COVERAGE FALLS OVER COST Coverage of GLP-1 drugs for obesity is falling as corporations and other health plan sponsors try to bring down premiums expected to be up by over 9% in 2027. About 14% of companies have already dropped or plan to drop the drugs in 2027.

根据雇员福利研究所2025年的一项研究,自费客户购买Zepbound和Wegovy的费用大约为每月299美元和349美元。雇主和其他医疗计划赞助方为这些药物每月支付617至766美元不等。CVS拒绝就支付的平均价格发表评论。

Zepbound and Wegovy can cost about $299 and $349 for cash-pay customers. Employers and other health plan sponsors pay between $617 and $766 monthly for the drugs, according to a 2025 study by the Employee Benefit Research Institute. CVS declined to comment on the average prices paid.

CVS健康公司首席医疗官艾米·康普顿-菲利普斯医生表示,制药商面向消费者的直接定价表明,他们以每月低于350美元的价格收费依然能够获利,同时还有助于降低整体医疗成本。美国的医疗支出高于世界上任何其他国家。

Dr Amy Compton-Phillips, chief medical officer at CVS Health, said that the drugmakers' direct-to-consumer prices suggest they can still profit by charging less than $350 a month, while also helping to lower overall healthcare costs. The United States pays more for healthcare than any other country.

她在拉斯维加斯HLTH USA会议召开前接受采访时表示:“我希望我们能早日实现这个价格。”CVS将于11月15在该会议上公布研究结果。

“I hope that we can reach that price sooner rather than later,” she said in an interview ahead of the HLTH USA conference in Las Vegas, where CVS will present the findings on November 15. The US government agreed on a deal with Lilly and Novo last year to pay $245 per month for injectable GLP-1 weight-loss drugs in an 18-month pilot testing their cost-effectiveness for Medicare beneficiaries aged 65 and older or with disabilities.

美国政府去年与礼来和诺和达成了协议,在为其18个月的试点项目中,每月支付245美元用于注射用GLP-1减肥药,以测试其对65岁及以上或残疾的联邦医疗保险受益人的成本效益。

HOSPITALIZATIONS FALL CVS said GLP-1 use for obesity, diabetes or other conditions was associated with 10-12% lower emergency room visits in the first and second year of use.

住院率下降 CVS表示,在用药的第一年和第二年,将GLP-1用于肥胖、糖尿病或其他疾病与急诊就医减少10%至12%相关。该公司查阅了第一年6万人和第二年2万人的人数记录。

It examined records for 60,000 people during the first year and 20,000 people for a second year. alysis of records for 4,000 people still taking the drug after three years showed a decrease in hospitalizations of 34-42%, according to the report.

根据该报告,对用药三年后仍在服药的4000人记录的分析显示,住院率下降了34%至42%。

When looking at spending and savings across those three years, plan sponsors saved $9,400 per person on medical bills, but spent $13,300 more on prescriptions, adding costs of $3,900 per person.

在审视这三年的支出和节省情况时,计划赞助方每人节省了9400美元的医疗账单,但在处方药上多花了13300美元,每人增加了3900美元的成本。

The company, which also operates pharmacy benefit manager Caremark and a network of retail pharmacies it plans to spin off, said the price at which GLP-1s start saving money overall depends on how healthy or sick a patient is.

该公司还运营着药品福利管理机构Caremark以及计划剥离的零售药房网络,其表示,GLP-1总体上开始省钱的价格取决于患者的健康或患病程度。

"An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes," said Compton-Phillips.

康普顿-菲利普斯说:“患有糖尿病的老年人比没有糖尿病的年轻肥胖者面临更高的住院风险。患者的风险越高,你获得投资回报的速度就越快。”

"The higher-risk the person is, the quicker you get to a return on investment."

阅读媒体原文 ↗